Katalyze AI has raised $10.5 million USD ($14.9 million CAD) in an all-equity seed round to deploy its agentic operating system inside large pharmaceutical companies. The startup's platform lets operations, engineering, and scientific staff build teams of AI agents that handle manufacturing and operational workflows - a direct attack on the eight-to-twelve-year timeline that typically bleeds over $2 billion per new drug.
The platform and the problem it targets
Katalyze is building what it calls an agentic operating system for pharma. Workers assemble AI agents to execute tasks across engineering, science, and manufacturing. The software is already running inside five of the world's 20 largest pharma firms, including Sanofi. Co-founder and CEO Reza Farahani frames the mission bluntly: "It takes eight to twelve years and more than two billion dollars to bring a drug to market. We want to cut that in half by 2030, and we're starting where the industry loses the most time: the operational and manufacturing arc."
A platform like this sits squarely in the operations domain. Pharmaceutical manufacturing and supply chains are thick with documentation, compliance checks, and handoffs. Giving operations teams the ability to deploy AI agents directly - without waiting on centralized data science queues - could squeeze months out of batch release, deviation management, and scale-up processes. For operations leaders learning to orchestrate AI agents in production environments, AI Learning Path for Operations Managers resources help bridge the gap between proof-of-concept and daily practice.
Funding and growth plans
The round was led by Bonfire Ventures and closed this spring. Katalyze now plans to expand its 40-person team, widen its catalogue of agents, and scale deployments with major pharma partners. The company did not disclose its valuation.
Dual headquarters and the talent map
Though domiciled in the US, Katalyze operates from both Toronto and San Francisco. Most of the founding team has Toronto roots. Farahani graduated from the University of Waterloo and previously sold Torontoworkforce software startup WFHomie. COO Shreyas Becker studied at the University of British Columbia, worked at Neo Financial, and led AI and data products for manufacturing and supply at Sanofi in Toronto. Montréal's Inovia Capital and Toronto's Ripple Ventures are also investors.
Farahani said the split gives Katalyze access to Silicon Valley venture capital while staying close to Toronto's concentrated pharma talent and industry base. For operations professionals, the geography matters: Toronto houses a dense cluster of pharmaceutical manufacturing and supply-chain roles, and the agents being built here are designed by people who've worked inside those exact functions. That practical lineage shows up in the platform's focus on operational workflows rather than broad R&D automation.
Why this matters for Operations
The platform puts an AI control layer directly into the hands of operations and manufacturing teams - not just data scientists or R&D groups. That means managers of production, quality, and supply chain will need to govern agent teams, validate their outputs, and redesign standard operating procedures that now involve machine actors. For those wanting a structured overview of how AI fits into daily operations leadership, AI for Operations curates training paths specific to the domain.
Katalyze's approach also signals a shift in where pharma innovation dollars are landing. Rather than funding new molecule discovery alone, serious money is flowing to the back end: the slow, expensive grind of making and delivering drugs at scale. Operations teams that can adopt and regulate agentic systems early will own a growing share of the timeline compression Farahani is targeting.
Your membership also unlocks:
